吸入型胰島素對胰島素市場造成的影響

本報告已在2011年12月21日停止出版。

簡介

目錄

Abstract

Introduction

The first inhaled formulation of rapid-acting insulin, Pfi zer' s Exubera, has just reached the market. Several other inhaled insulins are now in late-stage development. This technology is likely to impact the insulin market signifi cantly, adding new players and potentially changing medical practice by lowering current barriers to initiation of insulin therapy.

Get the Answers You Need to Shape Your Strategy

The long-term success of inhaled insulins will depend on third-party payer reimbursement policies, long-term safety data, and perceived convenience for the patient. What will provide emerging agents with a decisive competitive advantage? Including Exubera, which emerging inhaled insulin appears to have an edge in patient convenience?
Third-party payers are increasingly establishing policies that seek to contain the rising costs of health care. How have reimbursement policy makers responded to the availability of inhaled insulin? Aside from cost, what are the perceived disadvantages of inhaled insulins compared with injectable insulins?
Exubera will reap some benefi t from being the fi rst agent on the market, but the novelty of the technology will require Pfi zer to expend signifi cant resources to educate physicians and patients on its benefi ts. How important is Exubera to Pfi zer? Will Exubera be able to maintain its market advantage as competitors enter a market prepared for them by Pfi zer' s awareness campaign? Which inhaled insulin systems now in development will pose the greatest challenge to Exubera?

Table of Contents

• Executive Summary
• Strategic Considerations
• Stakeholder Implications
• Introduction
• Overview of Insulin Therapy
• Mechanism of Action
• Types of Manufactured Insulin
• Long-Acting Insulins
• Intermediate-Acting Insulins
• Short-Acting Insulins
• Drug Delivery
• Use of Insulin in the Treatment of Diabetes
• Type 1 Diabetes
• Type 2 Diabetes
• The Insulin Market, 2005
• Exubera
• How Exubera Works
• Development History
• Clinical Trials
• How Important Is Exubera to Pfizer?
• Other Inhaled Insulins in Development
• Eli Lilly and Alkermes' AIR Inhaled Insulin System
• Novo Nordisk and Aradigm' s AERx-iDMS System
• MannKind' s Technosphere
• The Outlook for Inhaled Insulins

Tables

• 1. Top-Selling Insulin Products, 2005
• 2. Pfizer' s Top-Selling Products in 2005 and Their Patent Expiries
• 3. Inhaled Insulins in Development

Figures

• 1. Growth of the Insulin and Antidiabetic Markets, 1995-2005
• 2. Expansion of Sales of Insulin Analogues, 2000-2005
• 3. Pfizer' s Pharmaceutical Sales, 2000-2005

相關商品

糖尿病相關市場調查報告書

胰島素給藥設備:全球開發平台分析機會評估及與到2017年為止的市場預測
Insulin Delivery Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
價格 : US $ 3995
出版日期 : 2012年01月

南非的糖尿病管理設備市場的機會及到2016年為止的成長趨勢預測
South Africa Diabetes Management Devices Market Outlook and Opportunities
價格 : US $ 2500
出版日期 : 2011年12月

荷蘭的糖尿病管理設備市場的機會及到2016年為止的成長趨勢預測
Netherlands Diabetes Management Devices Market Outlook and Opportunities
價格 : US $ 2500
出版日期 : 2011年12月

Decision Resources, Inc.發行的製藥相關市場調查報告書

傳染病疫苗開發平台:競爭檢討

Special Report: The Infectious Disease Vaccine Pipeline--A Competitive Review

價格 : US $ 9200

出版日期 : 2011年06月

感染疾病疫苗:未滿足需求和對醫藥品產業來說的機會

Special Report: Infectious Disease Vaccines--Unmet Needs and Opportunities for Pharma

價格 : US $ 9200

出版日期 : 2011年06月

自閉症譜系障礙:高未滿足需求創造出很大的市場機會

Special Report: Autism Spectrum Disorders--High Unmet Needs Create Significant Market Opportunities

價格 : US $ 9200

出版日期 : 2011年06月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!